Screener
Denali Therapeutics Inc. DNLI Cash, Cash Equivalents, and Marketable Securities
Cash, Cash Equivalents, and Marketable Securities at other companies
Other financials
Where this comes from
Reported directly by Denali Therapeutics Inc. in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecurities.
The source filing: Denali Therapeutics Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:08 PM EDT
- Fiscal quarter
- Q4 FY2026
- Calendar quarter
- Q4 2026
- Accession
- 0001714899-26-000097
| Line item | Amortized Cost | Unrealized Holding Gains | Unrealized Holding Losses | Aggregate Fair Value |
|---|---|---|---|---|
| U.S. government treasuries | $409,364 | $20 | $(555) | $408,829 |
| Corporate debt securities | 100,342 | 16 | (246) | 100,112 |
| Total short-term marketable securities | 509,706 | 36 | (801) | 508,941 |
| Long-term marketable securities: | ||||
| U.S. government treasuries | 164,059 | — | (658) | 163,401 |
| Corporate debt securities | 66,328 | — | (195) | 66,133 |
| Total long-term marketable securities | 230,387 | — | (853) | 229,534 |
| Total | $740,093 | $36 | $(1,654) | $738,475 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Denali Therapeutics Inc.'s cash, cash equivalents, and marketable securities?
- Denali Therapeutics Inc. (DNLI) reported cash, cash equivalents, and marketable securities of $508.94M in Q2 2026.
- How has Denali Therapeutics Inc.'s cash, cash equivalents, and marketable securities changed year-over-year?
- Denali Therapeutics Inc.'s cash, cash equivalents, and marketable securities decreased by 39.1% year-over-year, from $836.21M to $508.94M.
- What is the long-term trend for Denali Therapeutics Inc.'s cash, cash equivalents, and marketable securities?
- Over 5 years (2020 to 2025), Denali Therapeutics Inc.'s cash, cash equivalents, and marketable securities has grown at a -7.8% compound annual growth rate (CAGR), from $995.25M to $662.55M.
- What does cash, cash equivalents, and marketable securities mean?
- This represents the most liquid assets held by the company, including cash on hand, bank deposits, and short-term investments that can be readily converted into cash. It serves as the primary buffer for operational liquidity and potential capital allocation activities. Investors monitor this to assess the company's ability to meet short-term obligations and fund growth initiatives.
Ask your AI about Denali Therapeutics Inc.'s cash, cash equivalents, and marketable securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude